Strong PAT growth masks stalled organic revenue; AI inflection pending

₹615.2 Cr vs ₹498.6 Cr LY; organic +2%, rest FX/Novigo mix

Delivered: +81.6% PAT, 20.2% OPM vs 16.9% LY; holds

₹124.4 Cr adjusted EBITDA at 20.2% vs 16.9% LY, above 18–19% target

Stated but flagged as 'flat' by management; shift from many small to fewer large deals

Stated 'probably well over 35%' but not audited; early wins named (telecom, finserv, insurance)

Shifted from pure tech/OPD to agentic AI, PDLC, modernization. Large client wins named (telecom, finserv, entertainment, insurance). AI revenue now 35%+ vs early stage prior year.

TTM ACV bookings flat (₹82.9M); management acknowledged pressure. Shift to larger, longer-duration deals delays revenue recognition; deal duration now 3–4 months vs prior.

Mgmt restated 18–19% adjusted EBITDA as sustainable; Q2 delivered 20.2%, above target. Suggests conservatism or prior mix improvement.

Management candid: 2% organic growth this quarter, vs prior 3–4% aspiration. Blamed deal timing, not capability. This is materially below prior guidance.

Pressure is real due to AI PDLC adoption; our approach is proactive—AI-enabled models deliver 2–3x productivity, allowing us to reprice renewals and win new work with enhanced commitment.

ACV flatness is by design—fewer, larger transformational deals replace many small ones. Deal duration 3–4 months, revenue density higher. Organic 2%, but pipeline quality improving. We're winning on right motions, will reach double digits.

Organic +2% is lower than expectation due to deal timing; some Q2 deals shifted to Q3/Q4. This is a quarter thing, not structural. Deal conversion time longer due to agentic workflow adoption. For double-digit growth, industry needs to keep surprising.

Renewals at 85%+ rate, steady. Margins: we stated 18–19% as sustainable; we're delivering 20.2%. We've carefully managed currency uplifts, won't consume them on investments. High 18s is our respectable, sustainable range.

Enterprise is ~15% today, targeting 25–35% in 2–3 years. Growth will come from wallet share gains in larger accounts (transformation work) and new enterprise logos. ACV mix will shift; profitability per deal improves despite lower count.

BFSI is first-mover on AI PDLC and modernization. Healthcare/manufacturing have near-term project headwinds but strong AI/ML adoption trajectory. North America is largest market, will see highest growth with AI penetration.

Prior stated 3–4% constant-currency growth. Q2 delivered 2% organic, so below prior range. Management says 'double digits' is ambition, not near-term.

Q2 delivered 20.2%, above target. Management confident currency uplifts won't be spent; margin floor clear.

RSU expense ₹3.2Cr vs ₹6.2Cr prior Q (reduction). On-site hiring ramping for AI (FTE growth picking up North America).

Organic growth 2% vs prior 3–4% aspiration. Deal timing delays cited, but no clear recovery timeline. If organic doesn't reach 4%+ in next 2 qtrs, growth narrative collapses despite margin strength.

TTM ACV bookings flat at ₹82.9M. Shift from many small deals to fewer large transformational ones extends cycle to 3–4 months and defers revenue. If pipeline doesn't convert faster, Q3/Q4 could disappoint.

Novigo (Middle East) contributed to revenue in last 3 qtrs; ongoing geopolitical uncertainty. Management flagged Middle East volatility affecting client engagement. If Novigo delays/stalls, a 4–5% revenue headwind emerges.

AI revenue claimed at >35% of total (₹215+Cr), but not explicitly audited or detailed. Management said 'probably' when asked, and revenue mix shift could be driven by segmentation changes rather than genuine new wins.

EBITDA margin at 20.2%, above target of 18–19%. Management stated 18–19% as sustainable and respectable, suggesting further margin upside may be limited. If organic growth remains 2%, margin becomes the only growth story, creating valuation ceiling.